To validate whether miR-181a targets Bcl-2 in GC, immunoblotting assay was carried out and showed that Bcl-2 was about 2-fold higher in HGC-27 cells transfected with miR-181a inhibitor compared with the control (Fig. 5a). This evidence concerns the gene BCL2 and gastric cancer.